March 24, 2022Biotech Acquisition Co • April 18th, 2022 • Pharmaceutical preparations
Blade Therapeutics, Inc. (the “Company”) would like to amend the terms of your employment (and your underlying offer letter dated July 7, 2016 (the “Offer Letter”)) as set forth in this letter (this “Agreement”) to reflect the following adjustments to your compensation, which will be subject to the consummation of the transactions currently contemplated involving the acquisition of the Company by a special purpose acquisition company in order to complete a public offering of its common stock, following such transaction the Company or its successor (a) is required to file periodic reports pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, and (b) the Company’s common stock (or the successors common stock) is listed on one or more national securities exchanges or is quoted on NASDAQ or a successor quotation system (the “SPAC Transaction”) and shall be deemed effective upon January 1, 2022 (the “Effective Date”) following the consummation of the SPAC Transaction (t
March 24, 2022Biotech Acquisition Co • April 18th, 2022 • Pharmaceutical preparations
Blade Therapeutics, Inc. (the “Company”) would like to amend the terms of your employment (and your underlying offer letter dated February 1, 2021 (the “Offer Letter”) as set forth in this letter (this “Agreement”) to reflect the following adjustments to your compensation, which will be subject to the consummation of the transactions currently contemplated involving the acquisition of the Company by a special purpose acquisition company in order to complete a public offering of its common stock, following such transaction the Company or its successor (a) is required to file periodic reports pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, and (b) the Company’s common stock (or the successors common stock) is listed on one or more national securities exchanges or is quoted on NASDAQ or a successor quotation system (the “SPAC Transaction”) and shall be deemed effective upon January 1, 2022 (the “Effective Date”) following the consummation of the SPAC Transaction
February 1, 2021 Jean-Frédéric Viret, Ph.D. Dear Jean:Confidentiality Agreement • April 18th, 2022 • Biotech Acquisition Co • Pharmaceutical preparations
